

Fig. S1. Mass-spectrometry identified the refolded and activated recombinant EhCP4 protein. *A*. Refolded rEhCP4 that underwent autocatalytic processing was separated in a 12% SDS-polyacrylamide gel. Coomassie staining indicated a band of intermediate auto-processed EhCP4 fragment from the zymogen form (a), a band of mature EhCP4 (b), a band of degraded protein fragments (c). *B*. The same proteinase sample was reacted with DCG04 and blotted with streptavidin-alkaline phosphatase, indicating the mature rEhCP4. *C*. The Mass-spectrometry result of band a, indicating peptides from the pro-domain. *D*. The mass-spectrometry result of band b, indicating peptides from the mature enzyme. *E*. The mass-spectrometry result of band c, indicating peptides from the fusion protein's tag region and degraded fragments belonging to the enzyme proper.

He et al. Figure S2




Fig. S2. Cleavage of proteins of the host immune response by rEhCP4. *A.* Cleavage of C3. C3 (2 μg) was incubated with EhCP4 or EhCP1 and the fragments were resolved by a 4-50% SDS polyacrylamide gel. Coomassie stained bands resolved from cleavage of the α chain are marked with * (rEhCP1) and ** (rEhCP4). Inhibitors, WRR483 (rEhCP1) or E64 (rEhCP4) blocked the cleavage. *B.* rEhCP4-mediated cleavage of IgA. rEhCP4 mediated cleavage of human IgA (2 μg). Preincubation with E64 blocked the cleavage. Arrowheads indicate the fragments of the immunoglobulin heavy chain. *C.* rEhCP4 mediated cleavage of human IgG (2 μg). Preincubation with E64 blocked the cleavage. Arrowheads indicate the fragments of the immunoglobulin heavy chain. *D.* Cleavage of Pro-IL-18. rEhCP4 and recombinant pro-IL-18 (2 μg) were incubated. The decreased amount of pro-IL18 proteins are indicated with *. The degradation of pro-IL-18 was completely inhibited by pre-incubation with E-64. B-D, protein samples were separated with 15% SDS-polyacrylamide gels and stained with Coomassie blue.

He et al Figure S3




Fig. S3. Cleavage of villin and basement membrane laminin-1 by rEhCP4. **A.** Cleavage of villin-1. Immunoprecipitated human villin-1 was incubated with amebic lysate, rEhCP1 and rEhCP4. The proteinase activity (based on substrate Z-RR-AMC) of the amebic lysate was equivalent to that of rEhCP1. The resulting immunoblots were probed with villin-1 antibody. **B.** rEhCP4 and rEhCP1 degraded laminin-1. Laminin-1 (4 μ g) was incubated with rEhCP1 or rEhCP4 or both. The resulting laminin-1 fragments were analyzed by SDS-PAGE and the immunoblot was probed with anti-L-laminin-1 antibody. The EhCP1 specific inhibitor, WRR483 and the EhCP4 specific inhibitor, WRR605 were added at a concentration of 28 μ M. Intact laminin is indicated with an arrowhead.

He et al. Figure S4




Fig. S4. BODIPY labeled WRR-605 binds rEhCP4 and intracellular EhCP4. *A.* An optical section of a trophozoite shows co-localization of EhCP4 (green) and BODIPY-WRR605 (red) in the nuclear region of a trophozoite. *B.* Cellular distribution of BODIPY-WRR605 and Free BODIPY fluorescence dye in trophozoites. Z-stack thickness, 0.5 μ m; Scale bar, 5.0 μ m. *C.* The activated rEhCP4 was treated with BODIPY labeled WRR605 without (0 μ M) or with increasing concentrations of unlabeled WRR605, demonstrating competitive binding between WRR605 and BODIPY-WRR605. The arrow indicates the location of mature rEhCP4.